NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Lantern Pharma Q3 2025 Results and AI-Driven Oncology Pipeline FAQ
TL;DR
Lantern Pharma's LP-184 shows 48% clinical benefit rate, positioning it for competitive advantage in oncology markets with $15 billion annual potential.
Lantern Pharma's AI platform analyzed 200 billion data points to advance LP-184 through Phase 1a trials and establish a 0.39 mg/kg Phase 2 dose.
Lantern Pharma's AI-driven oncology programs aim to provide life-changing therapies for hundreds of thousands of cancer patients worldwide.
Lantern Pharma uses AI with 200+ machine learning algorithms to discover cancer drugs, achieving 48% clinical benefit in recent trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma reported completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, showing a 48% clinical benefit rate at or above the therapeutic dose threshold with favorable safety profile and strong biomarker correlations.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development using its proprietary RADR® AI and machine learning platform.
The company outlined plans for Phase 1b/2 studies in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) with STK11/KEAP1 co-mutations, and bladder cancer.
RADR® is Lantern's proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to accelerate oncology drug development.
Pharmacokinetic data established a recommended Phase 2 dose of 0.39 mg/kg for LP-184.
Lantern noted regulatory clarity for its pediatric CNS cancer program following a productive FDA Type C meeting.
Lantern's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.
The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
The company noted increased commercial interest for LP-284 and catalyst-rich progress across its pipeline, which includes both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program.
Lantern's lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials.
Curated from InvestorBrandNetwork (IBN)
